OHSU Study Aims To Halt Alzheimer's By Blocking Enzyme
Date: 7.4.2006
Inhibiting gamma secretase may prevent amyloid plaque build-up thought to trigger disease, but trials continue
PORTLAND, Ore. - Oregon Health & Science University is participating in a national study of a drug that may prevent Alzheimer's disease by blocking an enzyme that produces plaques believed to trigger the disorder.
OHSU is one of six sites around the country taking part in a double-blind, placebo-controlled study of the agent known as LY450139, a gamma secretase inhibitor manufactured by Indianapolis-based Eli Lilly and Co. Other study sites are in Indianapolis, St. Louis, Philadelphia, Seattle, and La Jolla, Calif. Lilly is funding the study.
"Source":[ http://www.ohsu.edu/ohsuedu/newspub/releases/031406enzyme.cfm].
Related articles
Alzheimer's, Parkinson's, type 2 diabetes similar at molecular level - Alzheimer's disease, Parkinson's disease, type 2 diabetes, the human version of mad cow disease, and other degenerative diseases are more closely related at the molecular level than scientists realized, a team reports this week in an advanced online publication of the journal Nature (2.5.2007)
